Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 673 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Boehringer Ingelheim Clear all
Completed Phase 3 Interventional Results available

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

NCT04157751
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo to Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
30
States / cities
Los Angeles, California • Orange, California • Torrance, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

NCT00400153
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg), Placebo via corresponding inhaler for blinding purposes
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
87
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

NCT04822701
View directory record Official record
Conditions
COVID-19
Interventions
BI 767551 intravenous, BI 767551 inhaled, Placebo intravenous, Placebo inhaled
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Miami Springs, Florida • Amarillo, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients

NCT00060801
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
BIIL 283 BS (Amelubent)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
35
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

NCT01867307
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Healthy
Interventions
Empagliflozin, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

NCT03820726
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder

NCT00796614
View directory record Official record
Conditions
Bladder, Neurogenic
Interventions
tamsulosin hydrochloride, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 16 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Los Angeles, California • Tampa, Florida • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

NCT02271906
View directory record Official record
Conditions
Lung Cancer
Interventions
BIBW 2992
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 16, 2026, 4:40 PM EDT
Recruiting Phase 3 Interventional

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

NCT07754461
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo, Survodutide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
88
States / cities
Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients

NCT00000962
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Diego, California • Worcester, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

NCT05213624
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 764198, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Huntsville, Alabama • San Francisco, California • South Gate, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Results available

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

NCT04937829
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
5 mg BI 1569912, 20 mg BI 1569912, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Garden Grove, California • Torrance, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

NCT01719003
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hyperglycemia
Interventions
Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd, Empagliflozin high dose qd, Empagliflozin low dose bid, Empagliflozin high dose bid
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
41
States / cities
Birmingham, Alabama • Manley Hot Springs, Alaska • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

NCT01297270
View directory record Official record
Conditions
Hepatitis C
Interventions
BI201335, PegIFN/RBV, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
78
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

NCT00054717
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
96
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Results available

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

NCT02348723
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Warfarin, Dabigatran Etexilate 150mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Little Rock, Arkansas • Fremont, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

NCT02392468
View directory record Official record
Conditions
Schizophrenia, Alzheimer Disease
Interventions
Placebo matching BI 409306 25 mg, Placebo matching BI 409306 50 mg, BI 409306 25 mg, BI 409306 50 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
La Jolla, California • Eatontown, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 16, 2026, 4:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Integrative-omics of the Disordered COPD Small Airway Epithelium

NCT02183818
View directory record Official record
Conditions
Smoking, COPD
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

NCT01132313
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 207127, BI 201335, Ribavirin, BI 207217
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
12
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Results available

A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine

NCT00344461
View directory record Official record
Conditions
HIV
Interventions
Nevirapine, FTC, and Tenofovir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00003328
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
porfiromycin, radiation therapy
Drug · Radiation
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Peoria, Illinois • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 21, 2010 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

NCT01559116
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Placebo, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Jasper, Alabama • Easley, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

NCT04521478
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
BI 1358894, Placebo, Quetiapine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
29
States / cities
Birmingham, Alabama • Garden Grove, California • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated No phase listed Observational

The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort

NCT02838108
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 16, 2026, 4:40 PM EDT